Overview

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott
Treatments:
Visilizumab